Jeffrey Yachnin - Concepedia

Author

Jeffrey Yachnin

Karolinska University Hospital

Also Known As

J Yachnin, J. Yachnin, Jeffrey R. Yachnin, Jeffrey Yachnin, Yachnin, Jeffrey

101

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Karolinska University Hospital Karolinska Institutet Uppsala University Hospital The University of Texas MD Anderson Cancer Center Science for Life Laboratory

About

Jeffrey Yachnin is an author at Karolinska University Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	1.3K
2	Natural Sciences	5	5	179
3	Biochemistry	3	3	91
4	Health Sciences	2	2	239
5	Biomolecular Engineering	1	1	36

Jeffrey Yachnin

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Sten Nilsson, Lars Franzén, Christopher Parker, The Lancet Oncology Bone-targeted Radium-223UrologyGenitourinary CancerMedicineCancer Treatment	2007	491
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer Sören Lehmann, Vladimir J.N. Bykov, Dina Ali, Journal of Clinical Oncology	2012	397
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial Johann S. de Bono, Nicole Concin, David S. Hong, The Lancet Oncology Innovatv 201Tisotumab VedotinMedicineImmunologyClinical Trials	2019	217
<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Clinical Cancer Research	2018	161
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Heikki Joensuu, Judith Fraser, Hans Wildiers, JAMA Oncology	2018	145
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel Pedram Kharaziha, Dimitris Chioureas, Dorothea Rutishauser, Oncotarget	2015	144
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis Markus Mayrhofer, Bram De Laere, Tom Whitington, Genome Medicine	2018	128
First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies Sandra Irenaeus, Dorte Nielsen, Peter Ellmark, International Journal of Cancer Intratumoral AdministrationAdverse EventsTumor ImmunologyCd40 Agonistic AntibodyCancer Immunosurveillance	2019	121
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Nature Cancer	2022	120
Pharmacokinetics of Oxaliplatin in Humans Hans Ehrsson, Inger Wallin, Jeffrey Yachnin Medical Oncology PharmacologyPharmacotherapyPharmacokineticsMedicine	2002	112

Page 1